{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tubes&page=24", "query": { "condition": "Fallopian Tubes", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 686, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tubes&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tubes&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T08:14:55.905Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01468909", "title": "Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 106, "start_date": "2011-12-12", "completion_date": "2018-01-27", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 142, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Burbank, California + 106 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01468909" }, { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2021-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT00345709", "title": "Elizabeth Registry for Low Grade Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "2003-09", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-10-07", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00345709" }, { "nct_id": "NCT07489287", "title": "GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-resistant Ovarian Cancer" ], "interventions": [ { "name": "GB-5267 - IV only", "type": "BIOLOGICAL" }, { "name": "GB-5267 -Combined IV and IP Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-08-18", "completion_date": "2030-08-18", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07489287" }, { "nct_id": "NCT03206047", "title": "Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2017-11-08", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Sacramento, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206047" }, { "nct_id": "NCT05483933", "title": "Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-resistant Ovarian Cancer", "Fallopian Tube Cancer", "Epithelial Ovarian Cancer", "Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Pegylated Liposomal Doxorubicin + SL-172154", "type": "DRUG" }, { "name": "Mirvetuximab + SL-172154", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shattuck Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 86, "start_date": "2022-08-18", "completion_date": "2025-02-07", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Duarte, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05483933" }, { "nct_id": "NCT00579787", "title": "Prospective Study Assessing Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Removal of the Cervix Versus Removal of the Uterus,Ovaries and Fallopian Tubes For Treatment Of Early Stage Cervical Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 72, "start_date": "2004-01", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2010-12-02", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579787" }, { "nct_id": "NCT00445549", "title": "Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2007-01", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2012-06-26", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445549" }, { "nct_id": "NCT02903771", "title": "Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Part A: Dose Escalation of Cantrixil", "type": "DRUG" }, { "name": "Part B: Expansion Cohort of Cantrixil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kazia Therapeutics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2016-12-05", "completion_date": "2020-03-24", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 3, "location_summary": "Oklahoma City, Oklahoma • Providence, Rhode Island • Dallas, Texas", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903771" }, { "nct_id": "NCT04598321", "title": "BrUOG 390: Neoadjuvant Treatment With Talazoparib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation", "BRCA2 Mutation", "Ovarian Cancer", "Fallopian Tube Cancer", "High Grade Serous Carcinoma" ], "interventions": [ { "name": "Talazoparib Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2021-03-29", "completion_date": "2022-12-06", "has_results": true, "last_update_posted_date": "2023-10-12", "last_synced_at": "2026-10-26T08:14:55.905Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04598321" } ] }